IRIS PubliCatt

PubliCatt è il repository istituzionale ad accesso aperto dell'Università Cattolica del Sacro Cuore, dove gli utenti autorizzati afferenti all'Ateneo provvedono direttamente e autonomamente a depositare e a rendere visibili le proprie pubblicazioni, inserendo i dati descrittivi del documento stesso ("metadati", quali il titolo, autore, abstract, etc.) e, laddove possibile, il testo della pubblicazione stessa (full-text).

PubliCatt utilizza la piattaforma IRIS (Institutional Research Information System) sviluppata da CINECA.

Prodotti recenti

A note on some sequential problems for the equilibrium value of a Vasicek process

We apply the Shiryaev’s sequential procedures to the Vasicek model. The problems of the sequential testing of two simple hypotheses and of the quickest detection of an abrupt change, both concerning the equilibrium value of the process, are faced. The solutions to these optimal...

Blinatumomab as a successful and safe therapy in Down syndrome patients with relapsed/refractory b-precursor acute lymphoblastic leukaemia: Case reports and literature review

n/a

Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group

Because the efficacy of new drugs reported in trials may not translate into similar results when used in the real-life, we analyzed the efficacy of idelalisib and rituximab (IR) in 149 patients with relapsed/refractory chronic lymphocytic leukemia treated at 34 GIMEMA centers. Medi...

Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs

Autoimmune cytopenias (AICs) affect 5% to 9% of patients with chronic lymphocytic leukemia (CLL). Targeted drugs—ibrutinib, idelalisib, and venetoclax—have a prominent role in the treatment of CLL, but their impact on CLL-associated AICs is largely unknown. In this study, we evaluated the&#x...

Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study

n/a

IRIS PubliCatt

Prodotti recenti

A note on some sequential problems for the equilibrium value of a Vasicek process

Blinatumomab as a successful and safe therapy in Down syndrome patients with relapsed/refractory b-precursor acute lymphoblastic leukaemia: Case reports and literature review

Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group

Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs

Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study

Scopri

Link utili